{"id":"W4410820333","doi":"10.1200/jco.2025.43.16_suppl.8014","title":"Clinical and molecular characteristics of early progressors (EPs) and long-term progression-free survivors (LTPs) from the phase 3 ADRIATIC trial of consolidation durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Durvalumab; Medicine; Placebo; Chemoradiotherapy; Internal medicine; Oncology; Phases of clinical research; Clinical trial; Cancer; Pathology; Pembrolizumab; Immunotherapy; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001010796,0.0003453882,0.0007161869,0.0002573085,0.0002637827,0.0003746799,0.0003016813,0.0005479742,0.00265393],"category_scores_gemma":[0.0008232818,0.0001772264,0.000582239,0.0002072569,0.0002596138,0.0003920517,0.0003094114,0.001007426,0.0004342712],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002652751,"about_ca_system_score_gemma":0.0003209769,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005015411,"about_ca_topic_score_gemma":0.0008961768,"domain_scores_codex":[0.9997579,0.00007109588,0.00002371469,0.00004834199,0.00003695511,0.00006194496],"domain_scores_gemma":[0.9990007,0.0001918356,0.0001752219,0.00007560121,0.00005987339,0.0004967459],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5342804,0.008201398,0.3618252,0.0002945983,0.001465378,0.0006703355,0.0002293575,0.00223621,0.01726635,0.0001644306,0.004835651,0.06853066],"study_design_scores_gemma":[0.04042912,0.1336726,0.8149483,0.00004570224,0.001087964,0.001101811,0.0001472374,0.00191836,0.003014788,0.0002554074,0.003337002,0.00004181844],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977509,0.0002815315,0.00009502181,0.00004756053,0.00001377498,0.0001364117,0.001063914,0.000006224499,0.0006046296],"genre_scores_gemma":[0.996218,0.00009623048,0.00009311416,0.0001104205,0.00003473779,0.0001852722,0.002465475,0.000002676431,0.000794075],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00265393,"threshold_uncertainty_score":0.008878291,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06979469026144287,"score_gpt":0.5023767545804756,"score_spread":0.4325820643190327,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}